Pharmacological targeting of SF3a1-MDM4 splicing vulnerability in ovarian cancer - with rifaximin and antisense oligonucleotide
Favorite
Share
More Options
21

Open in WPS to view all 21 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
